@article {FUMET4011, author = {JEAN-DAVID FUMET and JULIE VINCENT and LEILA BENGRINE and AUDREY HENNEQUIN and LAURA GRANCONATO and REMI PALMIER and FRAN{\c C}OIS GHIRINGHELLI}, title = {Safety and Efficacy of Gemcitabine, Docetaxel, Capecitabine, Cisplatin as Second-line Therapy for Advanced Pancreatic Cancer After FOLFIRINOX}, volume = {40}, number = {7}, pages = {4011--4015}, year = {2020}, doi = {10.21873/anticanres.14395}, publisher = {International Institute of Anticancer Research}, abstract = {Background/Aim: The aim of this monocentric study was to evaluate the efficacy and tolerability of a polychemotherapy regimen based on gemcitabine, docetaxel, capecitabine, cisplatin (PDGX) as second-line for advanced pancreatic cancer after FOLFIRINOX. Patients and Methods: Patients received FOLFIRINOX as first-line regimen were retrospectively identified between January 2016 and January 2019. After disease progression or unacceptable toxicity, patients eligible for second-line therapy were treated in our center by PDGX. Results: During this period, 18 patients received PDGX regimen as second-line therapy. Main grade 3 toxicities were hematologic, which required dose adaptation in 14/18 patients. No toxic death was observed. Median second-line progression-free survival (PFS) and overall survival (OS) were 2,91 and 5,3 months, respectively. Total OS from the initiation of first-line was and 11,9 months. Conclusion: Second-line PDGX regimen after FOLFIRINOX failure is feasible, with notable toxicity profile and is associated with poor clinical outcomes.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/40/7/4011}, eprint = {https://ar.iiarjournals.org/content/40/7/4011.full.pdf}, journal = {Anticancer Research} }